vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Millrose Properties, Inc. (MRP). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $189.5M, roughly 1.5× Millrose Properties, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 64.5%, a 31.8% gap on every dollar of revenue.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Millrose Properties, Inc. is a U.S.-based real estate enterprise primarily focused on the acquisition, ownership, operation, and management of income-generating multi-family residential assets. Its core markets span the U.S. Mid-Atlantic and Southeast regions, and it also offers professional property management services to select third-party property owners.
ACAD vs MRP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $189.5M |
| Net Profit | $273.6M | $122.2M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 84.8% |
| Net Margin | 96.3% | 64.5% |
| Revenue YoY | 9.4% | — |
| Net Profit YoY | 90.3% | 285.8% |
| EPS (diluted) | $1.61 | $0.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $189.5M | ||
| Q3 25 | $278.6M | $179.3M | ||
| Q2 25 | $264.6M | $149.0M | ||
| Q1 25 | $244.3M | $82.7M | ||
| Q4 24 | $259.6M | — | ||
| Q3 24 | $250.4M | — | ||
| Q2 24 | $242.0M | — | ||
| Q1 24 | $205.8M | — |
| Q4 25 | $273.6M | $122.2M | ||
| Q3 25 | $71.8M | $105.1M | ||
| Q2 25 | $26.7M | $112.8M | ||
| Q1 25 | $19.0M | $39.8M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | — | ||
| Q2 24 | $33.4M | — | ||
| Q1 24 | $16.6M | — |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 84.8% | ||
| Q3 25 | 12.8% | 85.3% | ||
| Q2 25 | 12.2% | 85.1% | ||
| Q1 25 | 7.9% | 55.2% | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 7.4% | — |
| Q4 25 | 96.3% | 64.5% | ||
| Q3 25 | 25.8% | 58.6% | ||
| Q2 25 | 10.1% | 75.7% | ||
| Q1 25 | 7.8% | 48.1% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 8.0% | — |
| Q4 25 | $1.61 | $0.74 | ||
| Q3 25 | $0.42 | $0.63 | ||
| Q2 25 | $0.16 | $0.68 | ||
| Q1 25 | $0.11 | $0.39 | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.20 | — | ||
| Q1 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $35.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $5.9B |
| Total Assets | $1.6B | $9.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $35.0M | ||
| Q3 25 | $258.0M | $242.6M | ||
| Q2 25 | $253.6M | $66.6M | ||
| Q1 25 | $217.7M | $89.5M | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — | ||
| Q1 24 | $204.7M | — |
| Q4 25 | $1.2B | $5.9B | ||
| Q3 25 | $917.3M | $5.9B | ||
| Q2 25 | $822.4M | $5.9B | ||
| Q1 25 | $765.2M | $5.9B | ||
| Q4 24 | $732.8M | — | ||
| Q3 24 | $577.2M | — | ||
| Q2 24 | $516.7M | — | ||
| Q1 24 | $464.0M | — |
| Q4 25 | $1.6B | $9.3B | ||
| Q3 25 | $1.3B | $9.0B | ||
| Q2 25 | $1.2B | $8.0B | ||
| Q1 25 | $1.1B | $7.2B | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $976.9M | — | ||
| Q2 24 | $914.1M | — | ||
| Q1 24 | $855.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $3.7B |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | 30.05× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $3.7B | ||
| Q3 25 | $74.3M | $123.1M | ||
| Q2 25 | $64.0M | $109.1M | ||
| Q1 25 | $20.3M | $21.3M | ||
| Q4 24 | $40.4M | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | $25.0M | — | ||
| Q1 24 | $29.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | 30.05× | ||
| Q3 25 | 1.03× | 1.17× | ||
| Q2 25 | 2.40× | 0.97× | ||
| Q1 25 | 1.07× | 0.53× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
MRP
Segment breakdown not available.
